Clinical Trial Update: Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associated SCC [EARLY_Phase 1]

View source ↗

Summary

Early-phase 1 trial update reports completion of a study evaluating rigosertib in patients with Recessive Dystrophic Epidermolysis Bullosa-associated squamous c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Recessive Dystrophic Epidermolysis Bullosa
• Squamous Cell Carcinoma

Drugs mentioned

• Rigosertib (rigosertib)

Snippet

Sponsor: Thomas Jefferson University | Conditions: Recessive Dystrophic Epidermolysis Bullosa | EARLY_Phase 1 | Status: COMPLETED